Information Provided By:
Fly News Breaks for December 21, 2015
Dec 21, 2015 | 09:11 EDT
Susquehanna analyst Chris Rigg continues to believe Centene (CNC) shares look significantly undervalued on a pro-forma basis considering its post Health Net (HNT) earnings and revenue guidance. The analyst sees the potential for additional merger related upside from revenue and cost synergies as the transaction allows Centene to leverage Health Net's Medicare Advantage platform. Rigg reiterated his Positive rating and $87 price target on Centene shares.